Year |
Citation |
Score |
2024 |
Poole RA, Wang Q, Ray A, Takabe K, Opyrchal M, Katsuta E. Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients. Cancers. 16. PMID 38398074 DOI: 10.3390/cancers16040683 |
0.359 |
|
2023 |
Zhao Y, Liu Z, Liu G, Zhang Y, Liu S, Gan D, Chang W, Peng X, Sung ES, Gilbert K, Zhu Y, Wang X, Zeng Z, Baldwin H, Ren G, ... ... Wang Q, et al. Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. Cell Metabolism. 35: 1688-1703.e10. PMID 37793345 DOI: 10.1016/j.cmet.2023.09.004 |
0.612 |
|
2023 |
Palakurthi B, Fross SR, Guldner IH, Aleksandrovic E, Liu X, Martino AK, Wang Q, Neff RA, Golomb SM, Lewis C, Peng Y, Howe EN, Zhang S. Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. Nature Communications. 14: 2109. PMID 37055410 DOI: 10.1038/s41467-023-37727-y |
0.613 |
|
2023 |
Wang Q, Poole RA, Opyrchal M. Understanding and targeting erythroid progenitor cells for effective cancer therapy. Current Opinion in Hematology. PMID 37052294 DOI: 10.1097/MOH.0000000000000762 |
0.332 |
|
2021 |
Guldner IH, Golomb SM, Wang Q, Wang E, Zhang S. Isolation of mouse brain-infiltrating leukocytes for single cell profiling of epitopes and transcriptomes. Star Protocols. 2: 100537. PMID 34036283 DOI: 10.1016/j.xpro.2021.100537 |
0.754 |
|
2021 |
Kim J, Wang Q, Zhang S, Yoon S. Compressed sensing-based super-resolution ultrasound imaging for faster acquisition and high quality images. Ieee Transactions On Bio-Medical Engineering. PMID 33793396 DOI: 10.1109/TBME.2021.3070487 |
0.377 |
|
2021 |
Liu Y, Yang J, Shi Z, Tan X, Jin N, O'Brien C, Ott C, Grisoli A, Lee E, Volk K, Conroy M, Franz E, Bryant A, Campbell L, Crowley B, ... ... Wang Q, et al. In vivo selection of highly metastatic human ovarian cancer sublines reveals role for AMIGO2 in intra-peritoneal metastatic regulation. Cancer Letters. PMID 33524500 DOI: 10.1016/j.canlet.2021.01.024 |
0.782 |
|
2020 |
Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, Manning HC, Rathmell JC, Cook RS, Boothby MR, Chen J. Selective glutamine metabolism inhibition in tumor cells improves anti-tumor T lymphocyte activity in triple-negative breast cancer. The Journal of Clinical Investigation. PMID 33320840 DOI: 10.1172/JCI140100 |
0.573 |
|
2020 |
Golomb SM, Guldner IH, Zhao A, Wang Q, Palakurthi B, Aleksandrovic EA, Lopez JA, Lee SW, Yang K, Zhang S. Multi-modal Single-Cell Analysis Reveals Brain Immune Landscape Plasticity during Aging and Gut Microbiota Dysbiosis. Cell Reports. 33: 108438. PMID 33264626 DOI: 10.1016/j.celrep.2020.108438 |
0.67 |
|
2020 |
Guldner IH, Wang Q, Yang L, Golomb SM, Zhao Z, Lopez JA, Brunory A, Howe EN, Zhang Y, Palakurthi B, Barron M, Gao H, Xuei X, Liu Y, Li J, et al. CNS-Native Myeloid Cells Drive Immune Suppression in the Brain Metastatic Niche through Cxcl10. Cell. PMID 33113353 DOI: 10.1016/j.cell.2020.09.064 |
0.719 |
|
2020 |
Wang S, Raybuck A, Shiuan E, Cho SH, Wang Q, Brantley-Sieders DM, Edwards D, Allaman MM, Nathan J, Wilson KT, DeNardo D, Zhang S, Cook R, Boothby M, Chen J. Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity. Jci Insight. 5. PMID 32759497 DOI: 10.1172/Jci.Insight.139237 |
0.571 |
|
2020 |
Wang Q, Gao J, Di W, Wu X. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunology, Immunotherapy : Cii. PMID 32347357 DOI: 10.1007/s00262-020-02576-x |
0.322 |
|
2019 |
Wang Q, Guldner IH, Golomb SM, Sun L, Harris JA, Lu X, Zhang S. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. Nature Communications. 10: 3817. PMID 31444334 DOI: 10.1038/S41467-019-11729-1 |
0.778 |
|
2018 |
Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. International Immunopharmacology. 58: 125-135. PMID 29579717 DOI: 10.1016/j.intimp.2018.03.018 |
0.321 |
|
2017 |
Yang J, Joshi S, Wang Q, Li P, Wang H, Xiong Y, Xiao Y, Wang J, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3ζ loss leads to neonatal lethality by microRNA-126 downregulation-mediated developmental defects in lung vasculature. Cell & Bioscience. 7: 58. PMID 29118970 DOI: 10.1186/S13578-017-0186-Y |
0.447 |
|
2017 |
Joshi S, Yang J, Wang Q, Li P, Wang H, Zhang Q, Xiong Y, Pickering BF, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3ζ loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. American Journal of Cancer Research. 7: 1654-1664. PMID 28861322 |
0.578 |
|
2016 |
Guldner IH, Yang L, Cowdrick KR, Wang Q, Alvarez Barrios WV, Zellmer VR, Zhang Y, Host M, Liu F, Chen DZ, Zhang S. An Integrative Platform for Three-dimensional Quantitative Analysis of Spatially Heterogeneous Metastasis Landscapes. Scientific Reports. 6: 24201. PMID 27068335 DOI: 10.1038/Srep24201 |
0.728 |
|
2015 |
Wang Q, Ding H, Wang H, Li P, Liu B, Zhang K. Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors. Oncology Reports. 33: 179-84. PMID 25354531 DOI: 10.3892/or.2014.3574 |
0.358 |
|
2014 |
Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research. 24: 542-59. PMID 24675532 DOI: 10.1038/Cr.2014.37 |
0.571 |
|
2014 |
Wang Q, Ding H, Liu B, Li SH, Li P, Ge H, Zhang K. Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors. International Journal of Oncology. 44: 1277-83. PMID 24452693 DOI: 10.3892/ijo.2014.2271 |
0.406 |
|
2014 |
Rehman SK, Li SH, Wyszomierski SL, Wang Q, Li P, Sahin O, Xiao Y, Zhang S, Xiong Y, Yang J, Wang H, Guo H, Zhang JD, Medina D, Muller WJ, et al. 14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Research. 74: 363-73. PMID 24197133 DOI: 10.1158/0008-5472.Can-13-2016 |
0.633 |
|
2014 |
Sahin O, Wang Q, Brady S, Wang H, Chang C, Wong S, Muller W, Esteva F, Chang J, Yu D. 237: Sequential application of targeted therapies guided by biomarkers overcomes therapy resistance in rapidly evolving highly aggressive mammary tumors European Journal of Cancer. 50: S55. DOI: 10.1016/S0959-8049(14)50208-0 |
0.499 |
|
2012 |
Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Research. 72: 4417-28. PMID 22773664 DOI: 10.1158/0008-5472.Can-12-1339-T |
0.626 |
|
2011 |
Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 20: 341-56. PMID 21907925 DOI: 10.1016/J.Ccr.2011.07.017 |
0.592 |
|
2008 |
Wang Q, Li M, Wang Y, Zhang Y, Jin S, Xie G, Liu Z, Wang S, Zhang H, Shen L, Ge H. RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. Cancer Letters. 269: 127-38. PMID 18534745 DOI: 10.1016/j.canlet.2008.04.035 |
0.319 |
|
Show low-probability matches. |